Upcoming AWS Coverage on IDEXX Laboratories Post-Earnings Results

LONDON, UK / ACCESSWIRE / November 9, 2016 / Active Wall St. blog coverage looks at the headline from the French biopharmaceutical firm DBV Technologies S.A. (NASDAQ: DBVT) as the company announced on November 8, 2016, that it has completed the enrolment of Phase II study of Viaskin Milk for the treatment of patients with milk allergy. Reportedly, CMPA or Cow's Milk Protein Allergy is the most common infant food allergy worldwide and affects almost 3%-7% of the infants across the globe. CMPA is a spontaneous response of the immune system to Casein or Whey named proteins found in cow's milk. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

One of DBV Technologies' competitors within the Diagnostic Substances space, IDEXX Laboratories, Inc. (NASDAQ: IDXX), reported on November 01, 2016, revenues for Q3 2016. AWS will be initiating a research report on IDEXX Laboratories in the coming days.

Today, AWS is promoting its blog coverage on DBVT; touching on IDXX. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/registration-3/?symbol=DBVT

http://www.activewallst.com/registration-3/?symbol=IDXX

The MILES trial for evaluation of Viaskin Milk to check its efficacy and safety in children 2 to 17 years of age, diagnosed with CMPA, is under process. As a matter of fact, the Viaskin Milk patch is defined on the basis of DBV's flagship epicutaneous immunotherapy or EPIT. It is the proprietary technology solution which can administer biologically active compounds to the immune system through the skin. According to the present reports, blinded part of the MILES study is expected to be complete by the second half of 2017.

DBV's drive to cure CMPA

CMPA is one of the most common food allergies in infants and children alike. Previously, on August 21, 2016, DBV received FDA's Fastrack designation for Viaskin Milk for the treatment of paediatric patients with Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). As a matter of fact, Fastrack is a process developed by the FDA to facilitate the development and administration of drugs after ample reviews and safety checks to treat serious medical conditions and fill an unmet medical necessity.

No safety concerns were observed in Part A of the Viaskin Milk Efficacy and Safety (MILES), the study results which were presented at the 2016 AAAAI's annual meeting in Los Angeles, CA, on March 6, 2016. The phase II of the MILES study included the screening of 283 patients. Hence, the firm expects about 176 children with CMPA to be randomized 1:1:1:1 to receive one of the three doses of Viaskin Milk (150 μg, 300 μg, 500 μg) or placebo for 12 months.

Breaking down Viaskin Milk

Viaskin Milk is an under-development investigational therapy aimed at treatment of paediatric cow's milk protein allergy (CMPA) and Eosinophilic Esophagitis (EoE). The Viaskin Milk patch is developed on the EPIT technology, where biologically active compounds are administered through the skin.
Laurent Martin, the Chief Development Officer at DBVT, said in a statement that:

"CMPA is one of the most common food allergies in children and a life-threatening disease for which there currently is no approved treatment, representing a major public health challenge. We look forward to working closely with the FDA throughout the development process of Viaskin Milk."

Stock Performance

DBV Technologies' share price finished yesterday's trading session at $36.08, rising by 1.18%. A total volume of 54.05 thousand shares exchanged hands. The stock has advanced 6.97% and 19.75% in the last three months and past six months, respectively.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street